Arundic acid has been experimented in vitro and in vivo as a potential neuroprotective agent. It modulates
astrocyte activation by inhibiting the enhanced astrocytic synthesis of S-100β protein, responsible for inducing neuronal
death. The phase II clinical trials for the treatment of acute ischemic stroke, as well as clinical development in other neurodegenerative
diseases including amytrophic lateral sclerosis, Alzheimer's disease and Parkinson's disease are recently
completed. There is no review published in this area since its discovery as potential neuroprotective agent and the various
syntheses reported for this important non-natural compound. This review summarizes the studies towards the development
of arundic acid as a neuroprotective agent, the biological studies in vitro and in vivo, the phase II trials and the various efforts
made for its synthesis in the last two decades.
Keywords: Alzheimer‘s disease, astrocyte modulation, ischemic stroke, neuroprotection, Parkinson‘s disease, synthesis.
Rights & PermissionsPrintExport